{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:09:49Z","timestamp":1766048989372,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13318-018-0490-x","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T07:40:47Z","timestamp":1528962047000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4774","authenticated-orcid":false,"given":"Mohammad I.","family":"Saleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhad Bani","family":"Melhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanguin M.","family":"Al-Ramadhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Alzubiedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"issue":"3","key":"490_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000454819","volume":"45","author":"S Abad","year":"2017","unstructured":"Abad S, Vega A, Hernandez E, Merida E, de Sequera P, Albalate M, et al. Universal sustained viral response to the combination of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with\/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4. Am J Nephrol. 2017;45(3):267\u201372. https:\/\/doi.org\/10.1159\/000454819 .","journal-title":"Am J Nephrol"},{"key":"490_CR2","volume-title":"Surveillance for viral hepatitis\u2014United States, 2015","author":"Center for Disease Control and Prevention","year":"2015","unstructured":"Center for Disease Control and Prevention. Surveillance for viral hepatitis\u2014United States, 2015. United States: CDC; 2015."},{"key":"490_CR3","volume-title":"Chronic hepatitis C virus: advances in treatment, promise for the future","author":"ML Shiffman","year":"2011","unstructured":"Shiffman ML. Chronic hepatitis C virus: advances in treatment, promise for the future. New York: Springer; 2011."},{"issue":"9","key":"490_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558\u201367.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"490_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1365-2036.2006.02889.x","volume":"23","author":"EG Giannini","year":"2006","unstructured":"Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23(8):1055\u201365. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02889.x .","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"490_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2893.2010.01368.x","volume":"18","author":"EG Giannini","year":"2011","unstructured":"Giannini EG, Savarino V. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. J Viral Hepat. 2011;18(1):8\u201310. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01368.x .","journal-title":"J Viral Hepat"},{"key":"490_CR7","volume-title":"Rodak\u2019s hematology: clinical principles and applications","author":"EM Keohane","year":"2015","unstructured":"Keohane EM, Walenga JM, Smith LJ. Rodak\u2019s hematology: clinical principles and applications. Philadelphia: Elsevier Saunders; 2015."},{"issue":"9","key":"490_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1365-2036.2004.02192.x","volume":"20","author":"R Aspinall","year":"2004","unstructured":"Aspinall R, Pockros P. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20(9):917\u201329.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 13","key":"490_CR9","first-page":"S39","volume":"13","author":"G Bordin","year":"1995","unstructured":"Bordin G, Ballare M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995;13(Suppl 13):S39\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"490_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1053\/bega.2000.0144","volume":"14","author":"PA McCormick","year":"2000","unstructured":"McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Bailliere\u2019s Best Pract Res Clin Gastroenterol. 2000;14(6):1009\u201331. https:\/\/doi.org\/10.1053\/bega.2000.0144 .","journal-title":"Bailliere\u2019s Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"490_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1046\/j.1365-2141.2001.02824.x","volume":"113","author":"LE Adinolfi","year":"2001","unstructured":"Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113(3):590\u20135.","journal-title":"Br J Haematol"},{"key":"490_CR12","volume-title":"Mosby\u2019s 2014 nursing drug reference","author":"L Skidmore-Roth","year":"2014","unstructured":"Skidmore-Roth L. Mosby\u2019s 2014 nursing drug reference. 27th ed. Mosby: Skidmore Nursing Drug Reference; 2014.","edition":"27"},{"issue":"1","key":"490_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","volume":"132","author":"ML Shiffman","year":"2007","unstructured":"Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132(1):103\u201312. https:\/\/doi.org\/10.1053\/j.gastro.2006.11.011 .","journal-title":"Gastroenterology"},{"key":"490_CR14","volume-title":"Saunders nursing drug handbook 2014\u2014E-Book","author":"BB Hodgson","year":"2013","unstructured":"Hodgson BB, Kizior RJ. Saunders nursing drug handbook 2014\u2014E-Book. Amsterdam: Elsevier Health Sciences; 2013."},{"issue":"5","key":"490_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00003495-200969050-00005","volume":"69","author":"KP Garnock-Jones","year":"2009","unstructured":"Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69(5):567\u201376.","journal-title":"Drugs"},{"key":"490_CR16","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040170","author":"Y Deng","year":"2011","unstructured":"Deng Y, Madatian A, Wire MB, Bowen C, Park J, Williams D, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011. https:\/\/doi.org\/10.1124\/dmd.111.040170 .","journal-title":"Drug Metab Dispos"},{"key":"490_CR17","volume-title":"Drug information handbook.\u2009<\u20091996\/97\u2009>\u2009-2008\/2009: Lexi-Comp\u2019s clinical reference library","author":"Lexi-Comp Inc.","year":"2009","unstructured":"Lexi-Comp Inc., American Pharmaceutical Association. Drug information handbook.\u2009<\u20091996\/97\u2009>\u2009-2008\/2009: Lexi-Comp\u2019s clinical reference library. North American ed. Hudson, Ohio Washington, DC: Lexi-Comp, American Pharmaceutical Association; 2009. p. 2117."},{"issue":"3","key":"490_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/bcp.12244","volume":"77","author":"C Farrell","year":"2014","unstructured":"Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic\/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol. 2014;77(3):532\u201344.","journal-title":"Br J Clin Pharmacol"},{"key":"490_CR19","doi-asserted-by":"crossref","DOI":"10.1201\/b13613","volume-title":"The BUGS book: a practical introduction to Bayesian analysis","author":"D Lunn","year":"2012","unstructured":"Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book: a practical introduction to Bayesian analysis. Boca Raton: CRC Press; 2012."},{"issue":"7","key":"490_CR20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.clinthera.2015.03.024","volume":"37","author":"K Wu","year":"2015","unstructured":"Wu K, Thapar M, Farrell C, Hayes S, Guo H, Hou M, et al. Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in chinese patients with chronic primary immune thrombocytopenia. Clin Ther. 2015;37(7):1382\u201395. https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.024 .","journal-title":"Clin Ther"},{"issue":"6","key":"490_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/0091270010375427","volume":"51","author":"E Gibiansky","year":"2011","unstructured":"Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842\u201356.","journal-title":"J Clin Pharmacol"},{"key":"490_CR22","unstructured":"Gibiansky E, Mudd Jr P, Kamel Y, Kamel YM, editors. Population pharmacokinetics of eltrombopag in patients with cancer and healthy subjects. AAPS Annual Meeting; 2009."},{"issue":"4","key":"490_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Stat Methodol). 2002;64(4):583\u2013639.","journal-title":"J R Stat Soc Ser B (Stat Methodol)"},{"issue":"1","key":"490_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","volume":"14","author":"M Joerger","year":"2012","unstructured":"Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119\u201332.","journal-title":"AAPS J"},{"key":"490_CR25","volume-title":"Pharmacometrics: the science of quantitative pharmacology","author":"EI Ette","year":"2013","unstructured":"Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. New York: Wiley; 2013."},{"key":"490_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9780470693926","volume-title":"Systematic reviews in health care: meta-analysis in context","author":"M Egger","year":"2001","unstructured":"Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ; 2001.","edition":"2"},{"key":"490_CR27","volume-title":"Advanced methods of pharmacokinetic and pharmacodynamic systems analysis","author":"D D\u2019Argenio","year":"2006","unstructured":"D\u2019Argenio D. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Berlin: Springer; 2006."},{"issue":"12","key":"490_CR28","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/aje\/153.12.1222","volume":"153","author":"DB Dunson","year":"2001","unstructured":"Dunson DB. Commentary: practical advantages of Bayesian analysis of epidemiologic data. Am J Epidemiol. 2001;153(12):1222\u20136.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"490_CR29","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-017-0527-3","volume":"56","author":"MI Saleh","year":"2017","unstructured":"Saleh MI. A Bayesian approach for population pharmacokinetic modeling of pegylated interferon \u03b1-2a in hepatitis C patients. Clin Pharmacokinet. 2017;56(11):1369\u201379.","journal-title":"Clin Pharmacokinet"},{"key":"490_CR30","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037960","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, et al. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011. https:\/\/doi.org\/10.1124\/dmd.110.037960 .","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"490_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00280-013-2150-9","volume":"71","author":"S Hayes","year":"2013","unstructured":"Hayes S, Mudd PN, Ouellet D, Johnson BM, Williams D, Gibiansky E. Population PK\/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol. 2013;71(6):1507\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"490_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s11095-014-1594-x","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang J, Thapar M, Farrell C, Wire MB. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection. Pharm Res. 2015;32(6):2015\u201328.","journal-title":"Pharm Res."},{"key":"490_CR33","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Boca Raton: Taylor & Francis; 1982.","edition":"2"},{"key":"490_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/9781118541203","volume-title":"Handbook of metabolic pathways of xenobiotics","author":"P Lee","year":"2014","unstructured":"Lee P, Aizawa H, Gan L, Prakash C, Zhong D. Handbook of metabolic pathways of xenobiotics. New York: Wiley; 2014."},{"issue":"10","key":"490_CR35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/1440-1681.12451","volume":"42","author":"MI Saleh","year":"2015","unstructured":"Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015;42(10):1030\u20135.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"490_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic\u2013pharmacodynamic modeling and simulation","author":"PL Bonate","year":"2011","unstructured":"Bonate PL. Pharmacokinetic\u2013pharmacodynamic modeling and simulation. Berlin: Springer; 2011."},{"key":"490_CR37","volume-title":"Applied clinical pharmacokinetics 3\/E","author":"LA Bauer","year":"2014","unstructured":"Bauer LA. Applied clinical pharmacokinetics 3\/E. New York: McGraw-Hill Education; 2014."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0490-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T17:37:21Z","timestamp":1661449041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0490-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"14 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding has been received for the conduct of this study and\/or preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}